Navigation Links
Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
Date:1/16/2012

SCOTTSDALE, Ariz., Jan. 16, 2012 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant® Therapy System, announced today that Scott Brooks has joined the company in the newly created position of Chief Operating Officer. Scott is responsible for helping scale the organization's capabilities to support increased market penetration and broadened reimbursement.

(Logo: http://photos.prnewswire.com/prnh/20120109/LA31405LOGO)

Most recently Scott was President of sales, marketing and customer service at BSN Medical located in Charlotte, NC. He led a team of 190 people in the US and Canada. Prior to that, Scott was the VP of Sales and National Accounts at Kinetic Concepts Inc. (KCI), the marketer of the wound VAC. At KCI he managed a team of sales and national accounts professionals who sold advanced wound care, critical care, and bariatric care devices in the US to hospitals, nursing homes, and homecare. Scott served on the KCI management team as the company emerged into a global leader. His experience includes successful leadership positions with The Hill-Rom Company, Kimberly Clark Health Care, and Covidien.

"Scott is a mission focused, strategic, and process minded leader with experience scaling an organization," said Virginia Rybski, President and CEO of Regenesis. "We look forward to his contributions in building upon our performance based culture."

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

About the Provant® Therapy System

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

Contact: Regenesis Biomedical, Inc.
Scott Robey, Vice President Marketing
www.regenesisbio.com
480-970-4970 phone


'/>"/>
SOURCE Regenesis Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncobiologics Appoints Scott Canute, Former President of Eli Lilly and Genzyme, to its Board of Directors
2. Pioneering US/Scottish Alliance for Life Science and Clinical Informatics
3. Scotland Announces Goal to Double Life Sciences Contribution to Scottish Economy by 2020 at BIO
4. Scott Garrett Joins Water Street Healthcare Partners
5. TGen and Scottsdale Healthcare researchers discover microRNA role in brain metastasis
6. Scott & White Healthcare President and CEO Alfred B. Knight, M.D. to Retire in 2011, Will Lead Foundation
7. Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing
8. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
9. SIRO Group Appoints Scott L. Spector as President, Strategic Operations, for its European Business
10. United States Recognizes Leading Scottish Scientist for Disease Research
11. MedTrust Online and Scottsdale Clinical Research Institute at Scottsdale Healthcare Announce Collaboration to Provide Cutting Edge Technology to Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... Georgia (PRWEB) , ... October 11, 2017 , ... Disappearing ... taking the lives of over 5.5 million people each year. Especially those living in ... greenovative startup Treepex - based in one of the most pollution-affected countries globally - ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
Breaking Biology News(10 mins):